Molecular pathways: hypoxia response in immune cells fighting or promoting cancer - PubMed (original) (raw)

Review

. 2012 Mar 1;18(5):1207-13.

doi: 10.1158/1078-0432.CCR-11-1591. Epub 2011 Dec 28.

Affiliations

PMID: 22205687
DOI: 10.1158/1078-0432.CCR-11-1591

Free article

Review

Molecular pathways: hypoxia response in immune cells fighting or promoting cancer

Asis Palazón et al. Clin Cancer Res. 2012.

Free article

Abstract

Both malignant and stromal components in tumors are influenced by the physiologic conditions of the microenvironment. Hypoxia is a prominent feature of solid tumors as a result of defective vascularization and intense metabolic activity. The gene-expression control mechanisms that adapt tissues to hypoxia are exploited by tumors to promote angiogenesis and vasculogenesis. The functions of infiltrating immune cells (macrophages and lymphocytes) and other stromal components are also influenced by a limited O(2) supply. Hypoxia-inducible factors (HIF) are the main molecular transcriptional mediators in the hypoxia response. The degradation and activity of HIF-1α and HIF-2α are tightly controlled by the fine-tuned action of oxygen-sensing prolyl and asparaginyl hydroxylase enzymes. Recent evidence indicates that hypoxia can modulate the differentiation and function of T lymphocytes and myeloid cells, skewing their cytokine-production profiles and modifying the expression of costimulatory receptors. This conceivably includes tumor-infiltrating lymphocytes. Hypoxia not only directly affects tumor-infiltrating leukocytes but also exerts effects on tumor cells and vascular cells that indirectly cause selective chemokine-mediated recruitment of suppressive and proangiogenic T-cell subsets. This review focuses on changes induced by hypoxia in immune cells infiltrating solid malignancies. Such changes may either promote or fight cancer, and thus are important for immunotherapy.

PubMed Disclaimer

Cited by

Advances in nanomaterials for treatment of hypoxic tumor.
Zou MZ, Liu WL, Chen HS, Bai XF, Gao F, Ye JJ, Cheng H, Zhang XZ. Zou MZ, et al. Natl Sci Rev. 2020 Jul 8;8(2):nwaa160. doi: 10.1093/nsr/nwaa160. eCollection 2021 Feb. Natl Sci Rev. 2020. PMID: 34691571 Free PMC article.
Heterogeneity of the tumor immune microenvironment and clinical interventions.
Jin Z, Zhou Q, Cheng JN, Jia Q, Zhu B. Jin Z, et al. Front Med. 2023 Aug;17(4):617-648. doi: 10.1007/s11684-023-1015-9. Epub 2023 Sep 20. Front Med. 2023. PMID: 37728825 Review.
Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.
Feng KC, Guo YL, Liu Y, Dai HR, Wang Y, Lv HY, Huang JH, Yang QM, Han WD. Feng KC, et al. J Hematol Oncol. 2017 Jan 5;10(1):4. doi: 10.1186/s13045-016-0378-7. J Hematol Oncol. 2017. PMID: 28057014 Free PMC article. Clinical Trial.
Overcoming Immune Evasion in Melanoma.
Eddy K, Chen S. Eddy K, et al. Int J Mol Sci. 2020 Nov 26;21(23):8984. doi: 10.3390/ijms21238984. Int J Mol Sci. 2020. PMID: 33256089 Free PMC article. Review.
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma.
Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, Nghiemphu L, Kaley T, Colman H, McCluskey C, Gaffey S, Smith TR, Cote DJ, Severgnini M, Yearley JH, Zhao Q, Blumenschein WM, Duda DG, Muzikansky A, Jain RK, Wen PY, Reardon DA. Nayak L, et al. Clin Cancer Res. 2021 Feb 15;27(4):1048-1057. doi: 10.1158/1078-0432.CCR-20-2500. Epub 2020 Nov 16. Clin Cancer Res. 2021. PMID: 33199490 Free PMC article. Clinical Trial.

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources
- Digital Repository of the University of Navarra
- Silverchair Information Systems
Other Literature Sources
- The Lens - Patent Citations Database